Alkermes PLC Company Profile (NASDAQ:ALKS)

About Alkermes PLC (NASDAQ:ALKS)

Alkermes PLC logoAlkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS). The Company's products include ARISTADA, VIVITROL, INVEGA SUSTENNA, XEPLION, INVEGA TRINZA, TREVICTA, RISPERDAL CONSTA, AMPYRA, FAMPYRA, BYDUREON, Aripiprazole lauroxil, ALKS 5461, ALKS 3831, ALKS 8700, ALKS 6428, ALKS 4230 and ALKS 7119. The Company's product platforms include injectable extended-release microsphere technology, LinkeRx technology, NanoCrystal technology and oral controlled release (OCR) technology. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ALKS
  • CUSIP: G0176710
  • Web: www.alkermes.com
Capitalization:
  • Market Cap: $8.81305 billion
  • Outstanding Shares: 153,190,000
Average Prices:
  • 50 Day Moving Avg: $58.61
  • 200 Day Moving Avg: $57.52
  • 52 Week Range: $41.93 - $63.40
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -151.92
  • P/E Growth: 50.62
Sales & Book Value:
  • Annual Revenue: $780.7 million
  • Price / Sales: 11.33
  • Book Value: $7.95 per share
  • Price / Book: 7.26
Profitability:
  • EBIDTA: ($107,340,000.00)
  • Net Margins: -25.61%
  • Return on Equity: -9.76%
  • Return on Assets: -6.85%
Debt:
  • Debt-to-Equity Ratio: 0.23%
  • Current Ratio: 3.60%
  • Quick Ratio: 3.30%
Misc:
  • Average Volume: 842,132 shs.
  • Beta: 2.23
  • Short Ratio: 10.21
 
Frequently Asked Questions for Alkermes PLC (NASDAQ:ALKS)

What is Alkermes PLC's stock symbol?

Alkermes PLC trades on the NASDAQ under the ticker symbol "ALKS."

How were Alkermes PLC's earnings last quarter?

Alkermes PLC (NASDAQ:ALKS) posted its earnings results on Thursday, April, 27th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.24) by $0.07. The business earned $191.80 million during the quarter, compared to analyst estimates of $195.79 million. Alkermes PLC had a negative net margin of 25.61% and a negative return on equity of 9.76%. Alkermes PLC's revenue was up 22.3% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.16) earnings per share. View Alkermes PLC's Earnings History.

When will Alkermes PLC make its next earnings announcement?

Alkermes PLC is scheduled to release their next quarterly earnings announcement on Thursday, July, 27th 2017. View Earnings Estimates for Alkermes PLC.

Where is Alkermes PLC's stock going? Where will Alkermes PLC's stock price be in 2017?

9 brokers have issued 12 month target prices for Alkermes PLC's stock. Their forecasts range from $51.00 to $78.00. On average, they expect Alkermes PLC's share price to reach $64.00 in the next year. View Analyst Ratings for Alkermes PLC.

What are analysts saying about Alkermes PLC stock?

Here are some recent quotes from research analysts about Alkermes PLC stock:

  • 1. Cowen and Company analysts commented, "ALKS reported Q1:17 results which came in below expectations." (4/28/2017)
  • 2. Cantor Fitzgerald analysts commented, "We remain cautious on ALKS stock because we believe it reasonable that the company may not be able to file for regulatory approval of ALKS 5461 (for treating major depressive disorder, MDD) with data from only one positive Phase 3 trial from the three studies that comprise the FORWARD clinical program. We also remain unconvinced that the company will successfully transition from a developer of drug formulation technologies (historically applied to partner's assets) to a developer of proprietary products. As noted in a report we recently published on the evolving multiple sclerosis (MS) landscape, we believe new market entrants could challenge existing drug franchises, in particular that of Biogen (BIIB, Neutral, $277). Even if ALKS 8700 does not reduce GI side effects relative to that experienced with Tecfidera, we believe ALKS would likely seek approval anyway given the hegemony BIIB enjoys in the MS fumarate drug market." (3/16/2017)
  • 3. According to Zacks Investment Research, "Alkermes boasts a diversified portfolio of products targeting major CNS disorders including schizophrenia, depression, addiction and multiple sclerosis. Revenues are driven not only by the company’s royalty and manufacturing business, but also by a strong performance of Vivitrol and Aristada. Alkermes sees both Vivitrol and Aristada as growth drivers. While Vivitrol should benefit from the newly passed legislation, CARA, securing reimbursement and access for Aristada also bodes well. Meanwhile, Alkermes’ progress with its pipeline has been impressive. Focus should be on the same as the company expects important data readouts over the next several quarters. Given its history of pipeline setbacks, any obstacle in the process of development of these candidates would weigh heavily on the stock. Stiff competition and dependence on partners remains a threat. Shares of the company have underperformed the broader industry year to date." (12/13/2016)
  • 4. J P Morgan Chase & Co analysts commented, "Importantly 5461 continued to be well tolerated, in line with prior studies. ALKS plans to meet with the FDA in early 1Q17 to discuss filing, and we continue to think positive FORWARD-5 data makes the totality of the data approvable [...] Further confirmation of an NDA filing based on data in hand, as well as, clarity on the filing timeline will be key in 2017." (10/21/2016)
  • 5. Morgan Stanley analysts commented, "We are raising our PT from $18 (11x old F17e of 1.64) to $23 (16x new F17e of $1.42) since downside from US MFA (antibiotic medicated feed additive) pressures appears limited." (9/2/2016)

Who are some of Alkermes PLC's key competitors?

Who are Alkermes PLC's key executives?

Alkermes PLC's management team includes the folowing people:

  • Richard F. Pops, Chairman, President, and CEO
  • James M. (Jim) Frates, SVP, CFO, and Treasurer
  • Gordon G. Pugh, SVP, COO, and Chief Risk Officer
  • Richard F. Pops, Chairman of the Board, Chief Executive Officer
  • Shane M. Cooke, President
  • James M. Frates, Chief Financial Officer, Senior Vice President
  • Kathryn L. Biberstein, Executive Vice President, Chief Administrative Officer, Chief Compliance Officer, Secretary
  • Elliot W. Ehrich M.D., Executive Vice President - Research and Development and Chief Medical Officer
  • Craig Hopkinson, Senior Vice President - Clinical Development and Medical Affairs, Chief Medical Officer
  • Michael J. Landine, Senior Vice President - Corporate Development

Who owns Alkermes PLC stock?

Alkermes PLC's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Meditor Group Ltd (0.67%), GW&K Investment Management LLC (0.20%), Fisher Asset Management LLC (0.07%), Roanoke Asset Management Corp NY (0.05%), APG Asset Management N.V. (0.04%) and Nisa Investment Advisors LLC (0.03%). Company insiders that own Alkermes PLC stock include David Joseph Gaffin, David W Anstice, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Institutional Ownership Trends for Alkermes PLC.

Who sold Alkermes PLC stock? Who is selling Alkermes PLC stock?

Alkermes PLC's stock was sold by a variety of institutional investors in the last quarter, including APG Asset Management N.V., Roanoke Asset Management Corp NY, Eqis Capital Management Inc., Independent Portfolio Consultants Inc., Bank of Montreal Can and Fisher Asset Management LLC. Company insiders that have sold Alkermes PLC stock in the last year include David Joseph Gaffin, Elliot Ehrich, Gordon G Pugh, Iain Michael Brown, James M Frates, Kathryn L Biberstein, Mark Stejbach, Michael J Landine, Paul J Mitchell, Richard F Pops, Robert A Breyer and Shane Cooke. View Insider Buying and Selling for Alkermes PLC.

Who bought Alkermes PLC stock? Who is buying Alkermes PLC stock?

Alkermes PLC's stock was purchased by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Mn Services Vermogensbeheer B.V., Insight Capital Research & Management Inc., US Bancorp DE, Daiwa SB Investments Ltd., Creative Planning, Aperio Group LLC and Capstone Asset Management Co.. View Insider Buying and Selling for Alkermes PLC.

How do I buy Alkermes PLC stock?

Shares of Alkermes PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Alkermes PLC's stock price today?

One share of Alkermes PLC stock can currently be purchased for approximately $57.73.


MarketBeat Community Rating for Alkermes PLC (NASDAQ ALKS)
Community Ranking:  2.9 out of 5 ( )
Outperform Votes:  275 (Vote Outperform)
Underperform Votes:  202 (Vote Underperform)
Total Votes:  477
MarketBeat's community ratings are surveys of what our community members think about Alkermes PLC and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Alkermes PLC (NASDAQ:ALKS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 4 Hold Ratings, 5 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $64.00 (10.86% upside)

Analysts' Ratings History for Alkermes PLC (NASDAQ:ALKS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/1/2017J P Morgan Chase & CoSet Price TargetBuy$78.00LowView Rating Details
6/13/2017Leerink SwannDowngradeOutperform -> Market Perform$68.00 -> $61.00MediumView Rating Details
6/7/2017Credit Suisse Group AGReiterated RatingBuy$70.00LowView Rating Details
4/28/2017Cowen and CompanyReiterated RatingBuyLowView Rating Details
4/24/2017Morgan StanleyReiterated RatingEqual Weight$62.00LowView Rating Details
4/3/2017Jefferies Group LLCReiterated RatingBuy$70.00MediumView Rating Details
3/16/2017Cantor FitzgeraldReiterated RatingNeutral$51.00MediumView Rating Details
9/27/2016Citigroup Inc.Boost Price TargetNeutral$44.00 -> $53.00N/AView Rating Details
7/29/2016Barclays PLCBoost Price TargetOverweight$65.00 -> $66.00N/AView Rating Details
5/26/2016Evercore ISIInitiated CoverageBuy$59.00N/AView Rating Details
2/22/2016Goldman Sachs Group, Inc. (The)Lower Price Target$57.00 -> $35.00N/AView Rating Details
1/21/2016GuggenheimReiterated RatingHoldN/AView Rating Details
(Data available from 7/22/2015 forward)

Earnings

Earnings History for Alkermes PLC (NASDAQ:ALKS)
Earnings by Quarter for Alkermes PLC (NASDAQ:ALKS)
Earnings History by Quarter for Alkermes PLC (NASDAQ ALKS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2017($0.01)N/AView Earnings Details
4/27/20173/31/2017($0.24)($0.31)$195.79 million$191.80 millionViewN/AView Earnings Details
2/15/2017Q416$0.04$0.15$206.38 million$213.50 millionViewListenView Earnings Details
11/2/2016Q316($0.06)($0.09)$186.39 million$180.20 millionViewListenView Earnings Details
7/28/2016Q216($0.10)($0.01)$174.15 million$195.20 millionViewListenView Earnings Details
4/28/2016Q116($0.20)($0.16)$153.64 million$156.80 millionViewListenView Earnings Details
2/25/2016Q415($0.18)($0.15)$161.24 million$163.10 millionViewListenView Earnings Details
10/29/2015Q315($0.21)($0.18)$151.77 million$152.70 millionViewListenView Earnings Details
7/30/2015Q215($0.10)($0.09)$142.80 million$151.40 millionViewListenView Earnings Details
4/30/2015Q115($0.03)$0.06$146.60 million$161.20 millionViewListenView Earnings Details
2/24/2015Q414$0.04$0.11$161.70 million$175.20 millionViewListenView Earnings Details
10/29/2014Q314($0.12)($0.13)$155.53 million$160.00 millionViewListenView Earnings Details
7/31/2014Q314$0.04($0.01)$146.91 million$153.40 millionViewListenView Earnings Details
4/30/2014Q1$0.10$0.11$135.79 million$130.21 millionViewListenView Earnings Details
2/27/2014Q114$0.20$0.27$142.93 million$154.50 millionViewListenView Earnings Details
10/31/2013$0.22$0.22$137.35 million$139.80 millionViewListenView Earnings Details
7/25/2013Q1 2014$0.22$0.30$131.50 million$138.60 millionViewListenView Earnings Details
5/23/2013Q4 2013$0.17$0.40$128.01 million$163.40 millionViewListenView Earnings Details
1/31/2013Q3 2013$0.23$0.34$130.81 million$135.90 millionViewListenView Earnings Details
11/1/2012Q213$0.11$0.17$121.62 million$124.00 millionViewN/AView Earnings Details
7/26/2012$0.16$0.39ViewN/AView Earnings Details
5/17/2012($0.16)($0.14)ViewN/AView Earnings Details
2/2/2012($0.21)($0.11)ViewN/AView Earnings Details
11/3/2011($0.10)($0.22)ViewN/AView Earnings Details
8/1/2011($0.11)$0.02ViewN/AView Earnings Details
5/18/2011($0.14)($0.14)ViewN/AView Earnings Details
2/3/2011($0.15)($0.06)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Alkermes PLC (NASDAQ:ALKS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20171($0.16)($0.16)($0.16)
Q3 20171($0.15)($0.15)($0.15)
Q4 20172($0.10)($0.05)($0.08)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Alkermes PLC (NASDAQ:ALKS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Alkermes PLC (NASDAQ:ALKS)
Insider Ownership Percentage: 5.34%
Institutional Ownership Percentage: 97.24%
Insider Trades by Quarter for Alkermes PLC (NASDAQ:ALKS)
Institutional Ownership by Quarter for Alkermes PLC (NASDAQ:ALKS)
Insider Trades by Quarter for Alkermes PLC (NASDAQ:ALKS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/3/2017Paul J MitchellDirectorSell1,500$58.11$87,165.00View SEC Filing  
6/8/2017Shane CookeInsiderSell10,000$60.33$603,300.00View SEC Filing  
6/1/2017Paul J MitchellDirectorSell1,500$57.49$86,235.00View SEC Filing  
5/24/2017Richard F PopsDirectorSell25,000$57.42$1,435,500.00View SEC Filing  
5/18/2017Michael J LandineSVPSell10,000$57.23$572,300.00View SEC Filing  
5/17/2017Richard F PopsDirectorSell50,000$58.19$2,909,500.00View SEC Filing  
5/11/2017Michael J LandineSVPSell10,000$57.01$570,100.00View SEC Filing  
5/10/2017Richard F PopsDirectorSell25,000$57.29$1,432,250.00View SEC Filing  
5/4/2017Shane CookeInsiderSell6,500$60.05$390,325.00View SEC Filing  
4/17/2017Elliot EhrichCMOSell10,000$56.60$566,000.00View SEC Filing  
4/3/2017Kathryn L BibersteinCAOSell15,000$57.68$865,200.00View SEC Filing  
4/3/2017Paul J MitchellDirectorSell1,500$58.31$87,465.00View SEC Filing  
3/29/2017Shane CookeInsiderSell2,070$60.00$124,200.00View SEC Filing  
3/23/2017Shane CookeInsiderSell6,030$60.01$361,860.30View SEC Filing  
3/21/2017Shane CookeInsiderSell1,900$60.09$114,171.00View SEC Filing  
3/20/2017Shane CookeInsiderSell300$60.00$18,000.00View SEC Filing  
3/15/2017Elliot EhrichCMOSell11,000$56.74$624,140.00View SEC Filing  
3/7/2017James M FratesSVPSell25,000$59.08$1,477,000.00View SEC Filing  
3/2/2017Robert A BreyerDirectorSell4,000$60.00$240,000.00View SEC Filing  
3/2/2017Shane CookeInsiderSell20,000$60.00$1,200,000.00View SEC Filing  
3/1/2017Paul J MitchellDirectorSell1,500$57.06$85,590.00View SEC Filing  
2/16/2017Elliot EhrichCMOSell11,000$56.68$623,480.00View SEC Filing  
2/1/2017Paul J MitchellDirectorSell1,500$54.45$81,675.00View SEC Filing  
1/17/2017Elliot EhrichCMOSell11,983$54.32$650,916.56View SEC Filing  
1/9/2017Mark StejbachSVPSell547$60.27$32,967.69View SEC Filing  
1/9/2017Shane CookeInsiderSell550$60.27$33,148.50View SEC Filing  
1/6/2017Elliot EhrichCMOSell10,000$59.44$594,400.00View SEC Filing  
1/6/2017Mark StejbachSVPSell9,453$60.05$567,652.65View SEC Filing  
1/6/2017Shane CookeInsiderSell9,450$60.06$567,567.00View SEC Filing  
1/4/2017Robert A BreyerDirectorSell4,000$60.00$240,000.00View SEC Filing  
1/3/2017David Joseph GaffinSVPSell2,500$55.40$138,500.00View SEC Filing  
1/3/2017Paul J MitchellDirectorSell1,500$55.40$83,100.00View SEC Filing  
12/16/2016Gordon G PughCOOSell21,458$57.65$1,237,053.70View SEC Filing  
12/15/2016Elliot EhrichCMOSell5,000$55.99$279,950.00View SEC Filing  
12/14/2016James M FratesSVPSell25,000$54.73$1,368,250.00View SEC Filing  
12/12/2016Elliot EhrichCMOSell16,983$55.15$936,612.45View SEC Filing  
12/8/2016Kathryn L BibersteinCAOSell14,145$56.13$793,958.85View SEC Filing  
12/7/2016James M. FratesSVPSell23,731$56.28$1,335,580.68View SEC Filing  
12/1/2016Kathryn L BibersteinCAOSell15,000$56.13$841,950.00View SEC Filing  
11/30/2016Michael J LandineSVPSell10,000$57.51$575,100.00View SEC Filing  
11/29/2016Richard F PopsDirectorSell30,000$56.98$1,709,400.00View SEC Filing  
11/22/2016Richard F PopsDirectorSell30,000$58.66$1,759,800.00View SEC Filing  
10/4/2016Paul J MitchellDirectorSell2,000$47.42$94,840.00View SEC Filing  
9/22/2016Elliot EhrichCMOSell5,000$50.83$254,150.00View SEC Filing  
9/16/2016Elliot EhrichCMOSell5,000$48.87$244,350.00View SEC Filing  
9/6/2016David Joseph GaffinSVPSell2,382$45.92$109,381.44View SEC Filing  
9/6/2016Elliot EhrichCMOSell10,000$46.02$460,200.00View SEC Filing  
9/6/2016Iain Michael BrownCAOSell29,976$45.92$1,376,497.92View SEC Filing  
9/6/2016Paul J MitchellDirectorSell2,000$45.92$91,840.00View SEC Filing  
8/4/2016Paul J MitchellDirectorSell2,000$49.48$98,960.00View SEC Filing  
7/27/2016Elliot EhrichCMOSell35,199$51.95$1,828,588.05View SEC Filing  
7/5/2016Paul J MitchellDirectorSell2,000$45.81$91,620.00View SEC Filing  
6/6/2016Paul J MitchellDirectorSell2,000$44.98$89,960.00View SEC Filing  
5/4/2016Paul J MitchellDirectorSell2,000$38.60$77,200.00View SEC Filing  
4/20/2016Michael J LandineSVPSell16,875$41.09$693,393.75View SEC Filing  
4/19/2016Richard F PopsCEOSell18,750$40.15$752,812.50View SEC Filing  
4/18/2016Iain Michael BrownCAOSell5,368$39.27$210,801.36View SEC Filing  
4/13/2016Elliot EhrichCMOSell11,698$37.66$440,546.68View SEC Filing  
4/12/2016Richard F PopsCEOSell25,000$37.79$944,750.00View SEC Filing  
4/4/2016Paul J MitchellDirectorSell2,000$35.65$71,300.00View SEC Filing  
3/22/2016Richard F PopsCEOSell25,000$31.77$794,250.00View SEC Filing  
3/15/2016Richard F PopsCEOSell25,000$31.40$785,000.00View SEC Filing  
3/4/2016Paul J MitchellDirectorSell2,000$32.80$65,600.00View SEC Filing  
3/3/2016David W AnsticeDirectorBuy5,000$32.87$164,350.00View SEC Filing  
2/4/2016Paul J. MitchellDirectorSell2,000$32.81$65,620.00View SEC Filing  
1/4/2016Robert A BreyerDirectorSell2,000$77.33$154,660.00View SEC Filing  
12/28/2015Mark StejbachinsiderSell10,000$80.24$802,400.00View SEC Filing  
12/23/2015Shane CookeinsiderSell18,000$77.23$1,390,140.00View SEC Filing  
12/7/2015Michael J. LandineSVPSell3,750$73.02$273,825.00View SEC Filing  
12/7/2015Richard F. PopsCEOSell37,500$72.06$2,702,250.00View SEC Filing  
12/1/2015Mark StejbachinsiderSell18,000$72.18$1,299,240.00View SEC Filing  
12/1/2015Michael J. LandineSVPSell10,000$72.18$721,800.00View SEC Filing  
12/1/2015Richard F. PopsCEOSell50,000$72.29$3,614,500.00View SEC Filing  
12/1/2015Robert A BreyerDirectorSell2,000$73.46$146,920.00View SEC Filing  
11/23/2015Shane CookeinsiderSell18,000$72.62$1,307,160.00View SEC Filing  
11/2/2015Mark StejbachinsiderSell18,000$72.06$1,297,080.00View SEC Filing  
11/2/2015Robert A BreyerDirectorSell2,000$71.80$143,600.00View SEC Filing  
10/29/2015Iain Michael BrownCAOSell10,822$69.99$757,431.78View SEC Filing  
10/23/2015Shane CookeinsiderSell18,000$62.03$1,116,540.00View SEC Filing  
10/13/2015James M. FratesCFOSell20,000$59.78$1,195,600.00View SEC Filing  
10/2/2015Robert A. BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
9/23/2015Shane CookeinsiderSell18,000$67.09$1,207,620.00View SEC Filing  
9/17/2015Michael J. LandineSVPSell10,000$71.20$712,000.00View SEC Filing  
9/17/2015Richard F. PopsCEOSell50,000$71.27$3,563,500.00View SEC Filing  
9/15/2015James M. FratesCFOSell20,000$71.10$1,422,000.00View SEC Filing  
9/10/2015Michael J. LandineSVPSell10,000$67.61$676,100.00View SEC Filing  
9/10/2015Richard F. PopsCEOSell50,000$67.57$3,378,500.00View SEC Filing  
9/1/2015Robert A BreyerDirectorSell2,000$61.43$122,860.00View SEC Filing  
8/24/2015Shane CookeinsiderSell18,000$57.65$1,037,700.00View SEC Filing  
7/23/2015Shane CookeInsiderSell18,000$69.79$1,256,220.00View SEC Filing  
7/20/2015Gordon G PughCOOSell18,750$70.10$1,314,375.00View SEC Filing  
7/14/2015James M FratesCFOSell20,000$65.79$1,315,800.00View SEC Filing  
7/1/2015Gordon G PughCOOSell13,750$65.13$895,537.50View SEC Filing  
7/1/2015Robert A BreyerDirectorSell2,000$64.90$129,800.00View SEC Filing  
6/23/2015Shane CookeInsiderSell18,000$66.84$1,203,120.00View SEC Filing  
6/17/2015Paul J MitchellDirectorSell15,500$65.10$1,009,050.00View SEC Filing  
6/16/2015Gordon G PughCOOSell32,977$63.11$2,081,178.47View SEC Filing  
6/16/2015James M FratesCFOSell10,000$58.63$586,300.00View SEC Filing  
6/1/2015Paul J MitchellDirectorSell1,500$60.78$91,170.00View SEC Filing  
6/1/2015Rebecca PetersonSVPSell21,983$60.05$1,320,079.15View SEC Filing  
5/26/2015Rebecca PetersonSVPSell1,322$60.49$79,967.78View SEC Filing  
5/26/2015Shane CookeInsiderSell18,000$60.31$1,085,580.00View SEC Filing  
5/22/2015Rebecca PetersonSVPSell28,558$61.71$1,762,314.18View SEC Filing  
5/12/2015James M FratesCFOSell10,000$59.34$593,400.00View SEC Filing  
5/4/2015Robert A BreyerDirectorSell2,000$60.00$120,000.00View SEC Filing  
5/1/2015Paul J MitchellDirectorSell1,500$55.79$83,685.00View SEC Filing  
4/23/2015Shane CookeInsiderSell18,000$62.55$1,125,900.00View SEC Filing  
4/21/2015Elliot EhrichCMOSell25,000$62.39$1,559,750.00View SEC Filing  
4/15/2015Gordon G PughCOOSell13,750$63.21$869,137.50View SEC Filing  
4/15/2015James M FratesCFOSell10,000$62.42$624,200.00View SEC Filing  
4/15/2015Paul J MitchellDirectorSell1,500$62.71$94,065.00View SEC Filing  
4/1/2015Robert A BreyerDirectorSell5,000$61.22$306,100.00View SEC Filing  
3/23/2015Shane CookeInsiderSell18,000$65.33$1,175,940.00View SEC Filing  
3/16/2015Elliot EhrichCMOSell18,000$66.81$1,202,580.00View SEC Filing  
3/10/2015James M FratesCFOSell10,000$66.25$662,500.00View SEC Filing  
3/5/2015Rebecca PetersonSVPSell17,737$71.37$1,265,889.69View SEC Filing  
3/2/2015Gordon G PughCOOSell15,000$71.39$1,070,850.00View SEC Filing  
3/2/2015Robert A BreyerDirectorSell5,000$70.86$354,300.00View SEC Filing  
2/23/2015Shane CookeInsiderSell18,000$74.29$1,337,220.00View SEC Filing  
2/17/2015Elliot EhrichCMOSell18,000$70.87$1,275,660.00View SEC Filing  
2/3/2015James M FratesCFOSell10,000$70.83$708,300.00View SEC Filing  
2/2/2015Gordon G PughCOOSell15,000$72.01$1,080,150.00View SEC Filing  
2/2/2015Robert A BreyerDirectorSell5,000$72.91$364,550.00View SEC Filing  
1/26/2015Gordon G PughCOOSell15,000$70.02$1,050,300.00View SEC Filing  
1/23/2015Shane CookeInsiderSell118,000$69.13$8,157,340.00View SEC Filing  
1/16/2015Floyd E BloomDirectorSell20,000$67.12$1,342,400.00View SEC Filing  
1/15/2015Elliot EhrichCMOSell18,375$66.45$1,221,018.75View SEC Filing  
1/15/2015James M FratesCFOSell10,000$66.86$668,600.00View SEC Filing  
1/7/2015Kathryn L BibersteinSVPSell28,374$65.00$1,844,310.00View SEC Filing  
1/2/2015Robert A BreyerDirectorSell5,000$58.57$292,850.00View SEC Filing  
12/11/2014Richard F PopsCEOSell100,000$56.04$5,604,000.00View SEC Filing  
12/10/2014James M FratesCFOSell18,870$56.07$1,058,040.90View SEC Filing  
12/9/2014Michael J LandineSVPSell18,000$56.82$1,022,760.00View SEC Filing  
12/5/2014Kathryn L BibersteinSVPSell15,433$57.61$889,095.13View SEC Filing  
12/1/2014Robert A BreyerDirectorSell5,000$54.64$273,200.00View SEC Filing  
11/19/2014James M FratesCFOSell8,000$53.86$430,880.00View SEC Filing  
11/13/2014Richard F PopsCEOSell100,000$52.87$5,287,000.00View SEC Filing  
11/7/2014James M FratesCFOSell13,303$49.98$664,883.94View SEC Filing  
11/6/2014Kathryn L BibersteinSVPSell20,000$50.54$1,010,800.00View SEC Filing  
11/3/2014Robert A BreyerDirectorSell5,000$50.05$250,250.00View SEC Filing  
10/23/2014Gordon G PughCOOSell14,577$45.00$655,965.00View SEC Filing  
10/8/2014James M FratesCFOSell16,000$41.00$656,000.00View SEC Filing  
10/1/2014Robert A BreyerDirectorSell5,000$42.59$212,950.00View SEC Filing  
9/24/2014James M FratesCFOSell16,000$45.29$724,640.00View SEC Filing  
9/18/2014Michael J LandineSVPSell15,000$45.60$684,000.00View SEC Filing  
9/17/2014Gordon G PughCOOSell14,900$45.04$671,096.00View SEC Filing  
9/17/2014Richard F PopsCEOSell50,000$44.89$2,244,500.00View SEC Filing  
9/10/2014James M FratesCFOSell16,000$43.18$690,880.00View SEC Filing  
9/2/2014Gordon G PughCOOSell1,100$45.08$49,588.00View SEC Filing  
9/2/2014Robert A BreyerDirectorSell5,000$45.12$225,600.00View SEC Filing  
8/27/2014James M FratesCFOSell16,000$45.08$721,280.00View SEC Filing  
8/26/2014Gordon G PughCOOSell16,000$45.00$720,000.00View SEC Filing  
8/13/2014James M FratesCFOSell15,000$41.37$620,550.00View SEC Filing  
8/11/2014Elliot EhrichCMOSell16,667$41.65$694,180.55View SEC Filing  
8/4/2014Gordon G PughCOOSell23,250$43.20$1,004,400.00View SEC Filing  
8/1/2014Robert A BreyerDirectorSell5,000$42.53$212,650.00View SEC Filing  
7/16/2014James M FratesCFOSell8,000$46.50$372,000.00View SEC Filing  
7/9/2014Elliot EhrichCMOSell16,667$47.41$790,182.47View SEC Filing  
7/9/2014James M FratesCFOSell7,000$47.41$331,870.00View SEC Filing  
7/3/2014Michael J LandineSVPSell7,000$51.31$359,170.00View SEC Filing  
7/2/2014Richard F PopsCEOSell50,000$51.69$2,584,500.00View SEC Filing  
7/1/2014Gordon G PughCOOSell16,000$46.49$743,840.00View SEC Filing  
7/1/2014Robert A BreyerDirectorSell5,000$50.57$252,850.00View SEC Filing  
6/26/2014Michael J LandineSVPSell10,000$49.92$499,200.00View SEC Filing  
6/25/2014James M FratesCFOSell7,000$50.22$351,540.00View SEC Filing  
6/25/2014Richard F PopsCEOSell50,000$49.87$2,493,500.00View SEC Filing  
6/20/2014Paul J MitchellDirectorSell17,000$50.00$850,000.00View SEC Filing  
6/19/2014Elliot EhrichCMOSell17,282$47.10$813,982.20View SEC Filing  
6/19/2014Michael J LandineSVPSell10,000$47.01$470,100.00View SEC Filing  
6/18/2014Richard F PopsCEOSell50,000$46.72$2,336,000.00View SEC Filing  
6/17/2014Kathryn L BibersteinSVPSell8,400$47.41$398,244.00View SEC Filing  
6/11/2014James M FratesCFOSell7,000$47.72$334,040.00View SEC Filing  
6/9/2014Elliot EhrichCMOSell16,667$48.15$802,516.05View SEC Filing  
6/2/2014Gordon G PughCOOSell16,000$45.34$725,440.00View SEC Filing  
6/2/2014Robert A BreyerDirectorSell5,000$45.18$225,900.00View SEC Filing  
5/30/2014Rebecca PetersonSVPSell21,981$45.86$1,008,048.66View SEC Filing  
5/23/2014Rebecca PetersonSVPSell1,321$45.08$59,550.68View SEC Filing  
5/22/2014Elliot EhrichCMOSell2,378$44.49$105,797.22View SEC Filing  
5/22/2014Gordon PughCOOSell15,700$45.25$710,425.00View SEC Filing  
5/22/2014Rebecca PetersonSVPSell19,807$44.02$871,904.14View SEC Filing  
5/21/2014Elliot EhrichCMOSell1,981$44.00$87,164.00View SEC Filing  
5/21/2014James FratesCFOSell7,000$44.30$310,100.00View SEC Filing  
5/20/2014Rebecca PetersonSVPSell20,307$44.05$894,523.35View SEC Filing  
5/19/2014Elliot EhrichCMOSell2,206$43.55$96,071.30View SEC Filing  
5/8/2014Floyd BloomDirectorSell10,000$46.16$461,600.00View SEC Filing  
5/5/2014Robert BreyerDirectorSell5,000$46.72$233,600.00View SEC Filing  
5/1/2014Paul MitchellDirectorSell1,000$45.90$45,900.00View SEC Filing  
4/9/2014James FratesCFOSell7,000$42.91$300,370.00View SEC Filing  
4/1/2014Paul MitchellDirectorSell1,500$44.14$66,210.00View SEC Filing  
3/19/2014James FratesCFOSell7,000$46.84$327,880.00View SEC Filing  
3/11/2014Wendy DixonDirectorBuy1,600$47.37$75,792.00View SEC Filing  
3/5/2014James FratesCFOSell7,000$47.78$334,460.00View SEC Filing  
2/18/2014Elliot EhrichCMOSell7,718$52.45$404,809.10View SEC Filing  
2/3/2014Paul MitchellDirectorSell1,500$48.15$72,225.00View SEC Filing  
1/21/2014Elliot EhrichCMOSell7,718$48.61$375,171.98View SEC Filing  
1/16/2014Elliot EhrichCMOSell14,555$47.35$689,179.25View SEC Filing  
1/16/2014Gordon PughCOOSell30,000$47.16$1,414,800.00View SEC Filing  
1/16/2014James FratesCFOSell7,000$47.40$331,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Alkermes PLC (NASDAQ:ALKS)
Latest Headlines for Alkermes PLC (NASDAQ:ALKS)
Source:
DateHeadline
finance.yahoo.com logoAlkermes to Host Conference Call to Discuss Second Quarter 2017 Financial Results
finance.yahoo.com - July 20 at 5:05 PM
nasdaq.com logoWe Did The Math FBT Can Go To $127 - Nasdaq
www.nasdaq.com - July 19 at 10:00 PM
finance.yahoo.com logoAlkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : July 19, 2017
finance.yahoo.com - July 19 at 4:58 PM
americanbankingnews.com logoZacks: Brokerages Expect Alkermes PLC (ALKS) to Post -$0.26 EPS
www.americanbankingnews.com - July 19 at 2:34 PM
americanbankingnews.com logoAlkermes PLC (ALKS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - July 19 at 8:15 AM
americanbankingnews.com logoAlkermes PLC (ALKS) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - July 18 at 12:13 PM
finance.yahoo.com logoETFs with exposure to Alkermes Plc : July 14, 2017
finance.yahoo.com - July 14 at 5:35 PM
americanbankingnews.com logoInsider Selling: Alkermes PLC (ALKS) Director Sells 1,500 Shares of Stock
www.americanbankingnews.com - July 6 at 8:04 PM
seekingalpha.com logoAlkermes Preliminary Phase 3 Data Leaves A Welcomed Impression - Seeking Alpha
seekingalpha.com - July 5 at 9:30 PM
finance.yahoo.com logoAlkermes Plc breached its 50 day moving average in a Bullish Manner : ALKS-US : July 4, 2017
finance.yahoo.com - July 4 at 5:49 PM
americanbankingnews.com logoAlkermes PLC (NASDAQ:ALKS) Given a $78.00 Price Target by J P Morgan Chase & Co Analysts
www.americanbankingnews.com - July 3 at 5:10 PM
finance.yahoo.com logoAlkermes Presents Phase III Data on Schizophrenia Candidate
finance.yahoo.com - July 3 at 3:38 PM
nasdaq.com logoCARA In Pain, ALKS Enlightened, FDA Expands Approved Use Of AMGN's Vectibix - Nasdaq
www.nasdaq.com - June 30 at 8:49 PM
seekingalpha.com logoAlkermes Data Don't Enlighten - Seeking Alpha
seekingalpha.com - June 30 at 3:46 PM
News IconBRIEF-Alkermes announces positive preliminary topline results
www.businessinsider.com - June 30 at 2:52 AM
streetinsider.com logoAlkermes plc (ALKS) Reports Positive Preliminary Topline Results From Phase 3 ...
www.streetinsider.com - June 29 at 9:51 PM
streetinsider.com logoAlkermes plc (ALKS) Reports Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS ... - StreetInsider.com
www.streetinsider.com - June 29 at 4:42 PM
finance.yahoo.com logoAlkermes Announces Positive Preliminary Topline Results From Phase 3 Antipsychotic Efficacy Study of ALKS 3831 for Treatment of Schizophrenia
finance.yahoo.com - June 29 at 4:42 PM
americanbankingnews.com logoAlkermes PLC (ALKS) Expected to Announce Quarterly Sales of $217.77 Million
www.americanbankingnews.com - June 25 at 9:46 AM
americanbankingnews.com logoAlkermes PLC (ALKS) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - June 23 at 11:32 AM
seekingalpha.com logoAlkermes May Have Lucky Investors Doing A Happy Jig - Seeking Alpha
seekingalpha.com - June 20 at 4:02 PM
finance.yahoo.com logoAlkermes Plc – Value Analysis (NASDAQ:ALKS) : June 20, 2017
finance.yahoo.com - June 20 at 4:02 PM
finance.yahoo.com logoAlkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : June 19, 2017
finance.yahoo.com - June 19 at 3:34 PM
americanbankingnews.com logoBrokers Set Expectations for Alkermes PLC's Q4 2017 Earnings (ALKS)
www.americanbankingnews.com - June 15 at 11:58 AM
streetinsider.com logoAlkermes plc (ALKS) Initiates Study 217 for ALKS 5461 for MDD - StreetInsider.com
www.streetinsider.com - June 14 at 3:28 PM
americanbankingnews.com logoAlkermes PLC (ALKS) Lowered to "Market Perform" at Leerink Swann
www.americanbankingnews.com - June 13 at 8:14 AM
streetinsider.com logoAlkermes plc (ALKS) Initiates Study 217 for ALKS 5461 for MDD
www.streetinsider.com - June 12 at 4:29 PM
finance.yahoo.com logoAlkermes Announces Initiation of Study 217 for ALKS 5461 for Treatment of Major Depressive Disorder
finance.yahoo.com - June 12 at 4:29 PM
finance.yahoo.com logoAlkermes Looks To Capitalize On Opioid Epidemic Through Aggressive Lobbying
finance.yahoo.com - June 12 at 4:29 PM
nasdaq.com logoAlkermes Begins Supportive Study In ALKS 3831 ENLIGHTEN Development Program
www.nasdaq.com - June 9 at 8:41 PM
streetinsider.com logoAlkermes plc (ALKS) Commences Phase 3 Study of ALKS 3831 in Young Adult Patients - StreetInsider.com
www.streetinsider.com - June 9 at 3:41 PM
americanbankingnews.com logoInsider Selling: Alkermes Plc (ALKS) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - June 8 at 7:28 PM
finance.yahoo.com logoAlkermes Announces Initiation of Phase 3 Study of ALKS 3831 in Young Adult Patients
finance.yahoo.com - June 8 at 4:09 PM
finance.yahoo.com logoAlkermes to Present at Goldman Sachs 38th Annual Global Healthcare Conference
finance.yahoo.com - June 8 at 4:09 PM
americanbankingnews.com logoAlkermes Plc (ALKS) Receives Buy Rating from Credit Suisse Group AG
www.americanbankingnews.com - June 7 at 8:20 AM
nasdaq.com logoAlkermes: FDA Approves Two-Month ARISTADA To Treat Schizophrenia - Quick Facts
www.nasdaq.com - June 6 at 8:22 PM
finance.yahoo.com logoFDA Approves Two-Month ARISTADA® for Treatment of Schizophrenia
finance.yahoo.com - June 6 at 8:51 AM
nasdaq.com logoAlkermes (ALKS) Up 2.5% Since Earnings Report: Can It Continue? - Nasdaq
www.nasdaq.com - May 31 at 3:28 PM
streetinsider.com logoAlkermes plc (ALKS) Names Craig Hopkinson, M.D., as CMO, SVP - StreetInsider.com
www.streetinsider.com - May 31 at 3:28 PM
finance.yahoo.com logoAlkermes (ALKS) Up 2.5% Since Earnings Report: Can It Continue?
finance.yahoo.com - May 31 at 11:09 AM
finance.yahoo.com logoAlkermes’ Corporate Presentation to Be Webcast at the Jefferies Healthcare Conference
finance.yahoo.com - May 30 at 8:35 PM
finance.yahoo.com logoAlkermes Appoints Craig Hopkinson, M.D., as Chief Medical Officer, and Senior Vice President, Clinical Development and Medical Affairs
finance.yahoo.com - May 30 at 11:55 AM
americanbankingnews.com logoZacks: Analysts Expect Alkermes Plc (ALKS) Will Announce Earnings of -$0.26 Per Share
www.americanbankingnews.com - May 30 at 7:38 AM
americanbankingnews.com logoAlkermes Plc (ALKS) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - May 29 at 8:38 AM
finance.yahoo.com logoAlkermes Plc breached its 50 day moving average in a Bearish Manner : ALKS-US : May 26, 2017
finance.yahoo.com - May 26 at 3:42 PM
americanbankingnews.com logoAlkermes Plc (ALKS) Director Richard F. Pops Sells 25,000 Shares
www.americanbankingnews.com - May 25 at 7:22 PM
seekingalpha.com logoAlkermes (ALKS) - ALKS 5461: Data Update At Society of Biological Psychiatry - Slideshow
seekingalpha.com - May 24 at 3:26 PM
americanbankingnews.com logoAlkermes Plc (ALKS) Given a $70.00 Price Target at Credit Suisse Group AG
www.americanbankingnews.com - May 19 at 8:28 PM
americanbankingnews.com logoAlkermes Plc (ALKS) SVP Sells $572,300.00 in Stock
www.americanbankingnews.com - May 19 at 7:58 PM
americanbankingnews.com logoAlkermes Plc (ALKS) Director Richard F. Pops Sells 50,000 Shares
www.americanbankingnews.com - May 19 at 7:40 PM

Social

Chart

Alkermes PLC (ALKS) Chart for Saturday, July, 22, 2017

This page was last updated on 7/22/2017 by MarketBeat.com Staff